Abstract

  • Population: 9-16 year-old seropositive individuals living in dengue endemic areas
  • Intervention: 3 doses of CYD-TDV administered 6 months apart
  • Comparison: Placebo
  • Outcome: Serious adverse events (non-dengue)
GRADE table